Phase 0 trials: Expediting the development of chemoprevention agents

Cancer Prevention Research

Volumn 4, Issue 3, 2011, Pages 288-292

  Kummar, Shivaani ^a   Doroshow, James H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN KINASE B INHIBITOR; SR 13668; UNCLASSIFIED DRUG;

CANCER PREVENTION; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG MICRODOSE; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SHORT SURVEY; SINGLE DRUG DOSE; STUDY DESIGN;

AGED; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955837533     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0013     Document Type: Short Survey

References (13)

1. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, et al. Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - A plan to move forward. Clin Cancer Res 2006;12:3661-97. (Pubitemid 44000248)
2. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006;295:2727-41.
3. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update on the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: Preventing breast cancer. Cancer Prev Res 2010;3:696-706.
4. US Food and Drug Administration. Guidance for industry, investigators, and reviewers: exploratory IND studies. 2006[cited 2010 6 Dec]; Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM078933.pdf
5. Kummar S, Kinders RJ, Rubinstein L, Parchment RE, Murgo AJ, Collins J. Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 2007;7:131-9.
6. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5.
7. Reid JM, Walden C, Qin R, et al. Phase 0 clinical chemoprevention trial of the AKT inhibitor SR13668. Cancer Prev Res 2011;4:347-353.
8. Boyd RA, Lalonde RL. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Clin Pharmacol Ther 2007;81:24-6.
9. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs. Clin Pharmacol Ther 2006;80:203-15. (Pubitemid 44313903)
10. Lappin G. Microdosing: current and the future. Bioanalysis 2010;2:509-17.
11. Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, et al. Designing phase 0 cancer clinical trials. Clin Cancer Res 2008;14:3675-82.
12. Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, et al. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res 2008;14:6877-85.
13. Rubinstein LV, Steinberg SM, Kummar S, Kinders R, Parchment RE, Murgo AJ, et al. The statistics of phase 0 trials. Stat Med 2010;29:1072-6.